Patents Examined by Jennifer Lamberski
-
Patent number: 11433149Abstract: Provided is a microsphere including a glass sphere core. The glass sphere core includes a first nuclide, a second nuclide and a diffusion region extending inwardly from an outer surface of the glass sphere core, with the second nuclide distributed in the diffusion region. The first nuclide and the second nuclide become radioactive after being activated by neutrons to produce radiations including ?-rays or ?-rays, or simultaneously ?-rays and ?-rays. A preparation method of a microsphere is also provided.Type: GrantFiled: February 20, 2019Date of Patent: September 6, 2022Assignee: PLATINUM OPTICS TECHNOLOGY INC.Inventors: Yu-Yu Tsai, Fu-Yu Chang, Chien-Liang Liu
-
Patent number: 11426395Abstract: The subject matter of the invention is PSMA inhibitor-HYNIC derivatives of PSMA-L1-L2-HYNIC formula, aromatic and aliphatic hydrazone derivatives, a radiopharmaceutical kit for 99mTc isotope labelling, radiopharmaceutical preparation and its application for prostate cancer and its metastasis diagnostics.Type: GrantFiled: September 3, 2019Date of Patent: August 30, 2022Assignee: NARODOWE CENTRUM BADAN JADROWYCH, OSRODEK RADIOIZOTOPOW POLATOMInventors: Arkadiusz Eugeniusz Sikora, Michal Maurin, Antoni Wlodzimierz Jaron, Justyna Pijarowska-Kruszyna, Monika Wyczólkowska, Barbara Janota, Marcin Radzik, Piotr Garnuszek, Urszula Karczmarczyk
-
Patent number: 11419543Abstract: A method for early stage pathology detection, location, imaging, evaluation, and treatment of cells and/or extracellular vesicles in the circulation.Type: GrantFiled: August 12, 2019Date of Patent: August 23, 2022Inventor: Gholam A. Peyman
-
Patent number: 11419953Abstract: Gadolinium based contrast agents (GCA) incorporating linear ligand chelation are fundamentally different from GCAs incorporating macrocyclic ligands. The macrocyclic\GCAs are synthesized by pathways characterized by the formation of a sequence of metastable complexes before obtaining the final stable complex. The synthesis of linear GCAs do not form metastable complexes. Commercial macrocyclic GCAs contain unstable metastable complexes. These metastable species are not regulated and quickly release free Gd3+ ions upon administration into the body. Gadolinium based contrast agents with near zero metastable species content and methods of synthesizing the same are disclosed. Gadolinium based contrast agents with long dissociation time in the body, and low free Gd3+ ion formation are obtained using a synthesis method which departs in novel ways from the traditional free Gd3+-based synthesis methods.Type: GrantFiled: November 23, 2021Date of Patent: August 23, 2022Assignee: Inventure, LLCInventors: Richard Deslauriers, Michael Milbocker
-
Patent number: 11413354Abstract: The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.Type: GrantFiled: July 10, 2019Date of Patent: August 16, 2022Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Ouathek Ouerfelli, Guangbin Yang, Sarah M. Cheal, Steve Larson
-
Patent number: 11406718Abstract: The present invention is directed to a method for identifying ductal leaks during pancreobiliary surgery in a human patient. The invention comprises the steps of: administering to a human patient undergoing pancreobiliary surgery an effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier; and observing the patient during the surgery for the presence of pancreobiliary ductal leaks.Type: GrantFiled: May 14, 2013Date of Patent: August 9, 2022Assignee: CHIRHOCLIN, INC.Inventor: Edward E. Purich
-
Patent number: 11408892Abstract: Methods, systems and computer-accessible medium for imaging a living cell or a living organism with bond-edited compounds using stimulated Raman scattering are disclosed. The method comprises the steps of introducing one or more bond-edited compounds into a live cell or a living organism, and detecting a vibrational tag in the cell or organism with stimulated Raman scattering. Also disclosed are methods for detecting a disease condition in a subject, methods for monitoring treatment for a disease condition, methods for screening an agent, methods for tracing a cellular process in a live cell using bond-edited compounds in combination with stimulated Raman scattering. Also disclosed are a composition for labeling a target cell with at least one bond-edited compound and devices for imaging bond-edited compounds by stimulated Raman scattering.Type: GrantFiled: December 18, 2015Date of Patent: August 9, 2022Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Wei Min, Lu Wei, Zhixing Chen, Fanghao Hu, Yihui Shen
-
Patent number: 11408894Abstract: Methods, systems and computer-accessible medium for imaging a living cell or a living organism with bond-edited compounds using stimulated Raman scattering are disclosed. The method comprises the steps of introducing one or more bond-edited compounds into a live cell or a living organism, and detecting a vibrational tag in the cell or organism with stimulated Raman scattering. Also disclosed are methods for detecting a disease condition in a subject, methods for monitoring treatment for a disease condition, methods for screening an agent, methods for tracing a cellular process in a live cell using bond-edited compounds in combination with stimulated Raman scattering. Also disclosed are a composition for labeling a target cell with at least one bond-edited compound and devices for imaging bond-edited compounds by stimulated Raman scattering.Type: GrantFiled: December 17, 2019Date of Patent: August 9, 2022Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Wei Min, Lu Wei, Zhixing Chen, Fanghao Hu, Yihui Shen
-
Patent number: 11406604Abstract: A method for manufacturing supported lipid bilayer on a porous silica nanoparticle with a ?-potential comprised between ?10 mV and +10 mV, the method comprising the steps of (a) providing a negatively charged supported lipid bilayer on a porous silica nanoparticle, wherein the negatively charged supported lipid bilayer has a ?-potential inferior to ?15 mV and wherein the negatively charged supported lipid bilayer comprised at least one phospholipid and; (b) adding a formulation of lipids, the lipids being 1,2-dioleoyl-3-trimethylammonium-propane alias DOTAP, cholesterol and at least one lipid different from DOTAP and cholesterol. The method further comprises the step of (c) performing an ultra-sonication for promoting DOTAP incorporation. The method can be supplemented by the step of addition of alginate and the step of cross-linking the alginate. Also a nanocapsule and composition comprising the nanocapsule.Type: GrantFiled: January 17, 2018Date of Patent: August 9, 2022Assignee: LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY (LIST)Inventors: Gaelle Corne, Jean-Sebastien Thomann
-
Patent number: 11395856Abstract: The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use.Type: GrantFiled: February 3, 2020Date of Patent: July 26, 2022Assignee: Lantheus Medical Imaging, Inc.Inventors: Simon P. Robinson, Robert W. Siegler, David C. Onthank, Nhung Tuyet Nguyen
-
Patent number: 11389552Abstract: One aspect of the invention provides a method for freeze-drying surfactant-stabilized microbubbles. The method includes: preparing vials comprising a mixture comprising microbubbles; partially submerging the vials in a chilled water bath, wherein the water bath has a sub-freezing temperature; placing the vials on a cooled shelf of a lyophilizer; freeze-drying the vials in the lyophilizer; and capping the freeze-dried vials. Another aspect of the invention provides a method for annealing surfactant-stabilized microbubbles. The method includes: preparing vials comprising a mixture comprising microbubbles; passing the vials in and out of liquid nitrogen (LN2) until the mixture is frozen; holding the vials at ?20° C.; placing the vials on a cooled shelf of a lyophilizer; freeze-drying the vials in the lyophilizer; and capping the freeze-dried vials.Type: GrantFiled: March 13, 2020Date of Patent: July 19, 2022Assignees: Thomas Jefferson University, Drexel UniversityInventors: Brian Edward Oeffinger, Margaret A. Wheatley, Rawan Shraim, Purva Vaidya, John Robert Eisenbrey
-
Patent number: 11389549Abstract: The present invention provides a 19F-MR/fluorescence multi-mode molecular imaging and drug loading diagnosis-treatment integrated nanoprobe, and a preparation method and an application. The nano-probe is a nanoparticle formed by coating a mixture of a surfactant containing a molecular targeting treatment drug and a fluorescent dye with a Perfluorocarbon (PFC) carrier; and by uniformly dispersing a mixed solution into water and glycerol, processing ultrasonically, removing a component which is not effectively coated, and purifying, the drug-loading nanoparticle capable of being used for 19 F-MR imaging may be prepared.Type: GrantFiled: April 23, 2020Date of Patent: July 19, 2022Assignee: Harbin Medical UniversityInventors: Xilin Sun, Lina Wu, Jie Yang, Kai Wang, Lili Yang, Haoxiang Li, Yingbo Li, Xiaona Li, Shuang Liu
-
Patent number: 11382990Abstract: Described herein are X-ray imageable polymers such as polymeric particles comprising bismuth as a radiopacifying agent, methods of making the polymers, and methods of using the polymers. The imageable particles may comprise a covalently bound compound which chelates the bismuth, for example, through a combination of nitrogen and oxygen atoms.Type: GrantFiled: October 31, 2017Date of Patent: July 12, 2022Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DHHSInventors: Ayele H. Negussie, Bradford Johns Wood
-
Patent number: 11369681Abstract: The invention discloses nanoparticles comprising compounds of calcium with anions such as phosphate, pyrophosphate, sulphate, silicate, carbonate, molybdate, or phosphosilicate that are doped with various ions. The nanoparticles are configured to produce heat (hyperthermia) under radio-wave (1 KHz-1000 GHz) exposure together with magnetism suitable for contrast imaging in MRI, X-ray absorption for computed tomography, near-infrared optical fluorescence for optical imaging, and/or radio-isotope emission for nuclear imaging or therapy. The nanoparticles can also be incorporated into micro-beads or other 3 dimensional scaffolds for image-guided (MRI, CT, NIR, nuclear) tissue regeneration, immunotherapy, vascular or tumor embolization, and/or chemo/radio-embolization.Type: GrantFiled: December 5, 2016Date of Patent: June 28, 2022Assignee: Amrita Vishwa VidyapeethamInventors: Manzoor Koyakutty, Anusha Ashokan, Vijay Harish, Shantikumar Nair
-
Patent number: 11369697Abstract: The present invention provides novel liposomes comprising Gd.DOTA.DSA (gadolinium (III) 2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N?-amido-methyl]-1,4,7,10- =tetra-azacyclododec-1-yl}-acetic acid), characterised in that the liposome further comprises a neutral, fully saturated phospholipid component (e.g. DSPC (1,2-distearoyl-sn-glycero-3-phospocholine]), which are of particular use in the preparation of magnetic resonance contrast agents for enhancing a magnetic resonance image of tumours in a mammal.Type: GrantFiled: March 20, 2017Date of Patent: June 28, 2022Assignees: UNITED KINGDOM RESEARCH AND INNOVATION, IMPERIAL INNOVATIONS LIMITEDInventors: Nazila Kamaly, Tammy Louise Kalber, Gavin David Kenny, Maya Thanou, Andrew David Miller, Jimmy David Bell
-
Patent number: 11351258Abstract: Methods and systems for radiation therapy involve administering a payload/combination of biocompatible high-Z and semiconductor NPs to tissue, such as a tumor or an eye. Ionizing radiation may be directed towards the payload, and ionized electrons generate Cerenkov radiation (CR). The CR interacts with semiconductor NPs to produce chemical species that are damaging to cells. The payload may be administered via injection or via a radiotherapy (RT) device that includes NPs in a biodegradable polymer matrix. Biodegradation of the polymer matrix, which results in release of its payload, may be remotely activated using, for example, electromagnetic or sound waves. The payload may include one or more immunologic adjuvants capable of promoting an immunologic response at remote sites (such as a metastatic tumors) that are separate from the site at which the NPs and adjuvants were administered.Type: GrantFiled: April 3, 2017Date of Patent: June 7, 2022Assignee: The Brigham and Women's Hospital, IncInventor: Wilfred F. Ngwa
-
Patent number: 11344636Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.Type: GrantFiled: February 6, 2018Date of Patent: May 31, 2022Assignee: Lantheus Medical Imaging, Inc.Inventors: Simon P. Robinson, Robert W. Siegler, Nhung Tuyet Nguyen, David C. Onthank, Tarakeshwar Vishwanath Anklekar, Charles Chester Van Kirk
-
Patent number: 11337665Abstract: Contrast agents for x-ray imaging including stabilized metal nanoparticles and encapsulated nanoparticles, as well as methods for imaging tissue with these agents, are disclosed. Also disclosed are methods of dual energy x-ray imaging using metal nanoparticle contrast agents or encapsulated metal nanoparticles.Type: GrantFiled: March 13, 2014Date of Patent: May 24, 2022Assignee: The Trustees of the University of PennsylvaniaInventors: Andrew D. A. Maidment, Anatoliy V. Popov, E. James Delikatny, Andrew Tsourkas, Roshan Karunamuni, Ajlan Al Zaki, Sara Gavenonis, David Cormode
-
Patent number: 11331284Abstract: The present invention is directed to 13C and/or 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drug resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent are useful against an autophagy mediated disease state and/or condition, for example, a Mycobacterium infection, Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer. Methods of treating autophagy disease states and/or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention.Type: GrantFiled: January 31, 2020Date of Patent: May 17, 2022Assignee: UNM Rainforest InnovationsInventors: Graham Timmins, Vojo P. Deretic
-
Patent number: 11324797Abstract: Plasmonics-active metal nanostars are provided that can be used for treating and detecting cells in a subject. The modes of treatment include a photo-activated drug, which is activated by the photo-response of the nanostar to electromagnetic stimulation; a thermally-activated drug, which is activated by a thermal response of the nanostar to electromagnetic stimulation; and the thermal response of the nanostar itself to electromagnetic stimulation, which may directly or indirectly cause the death of an undesirable cell. Uptake of nanostars by undesirable cells may also aid in detection, by enhancing contrast or otherwise transforming electromagnetic stimulation during imaging.Type: GrantFiled: October 17, 2017Date of Patent: May 10, 2022Assignee: DUKE UNIVERSITYInventors: Tuan Vo-Dinh, Hsiangkuo Yuan, Andrew Fales